Teleflex Incorporated (TFX) — ESG & Values Scores

Environment story

Teleflex demonstrates moderate environmental risk with significant disclosure gaps and unresolved supply-chain carbon accounting. The company faces material regulatory exposure from ethylene oxide sterilization regulations (EPA final rule April 2024, compliance deadline April 2026–2027) affecting contract sterilization partners, particularly Sterigenics U.S. LLC facilities in Georgia and New Mexico. No disclosed Scope 1, 2, or 3 emissions targets; no verified net-zero commitment identified. Climate change and natural-disaster supply-chain risks explicitly identified in 10-K risk factors. The company acknowledges EU MDR and climate-related disclosure requirements (California, EU) as emerging compliance obligations but provides no quantified emissions data, renewable-energy percentages, or decarbonization capex. Titanium-based bariatric product (Titan SGS) faced $100 million impairment due to GLP-1 competitive displacement, indicating product-portfolio sensitivity to market shifts but not environmental degradation per se.

Criticisms on file

Ethylene Oxide Sterilization Litigation & Regulatory Exposure – Contract sterilizer Sterigenics U.S. LLC facilities (Smyrna, GA; Santa Teresa, NM) subject to legal proceedings related to ethylene oxide use; 2019 letter from 15 state attorneys general to EPA urging stricter standards; EPA April 2024 final rule requires compliance by April 2026–2027.
Source: TFX 10-K Item 1A Risk Factors, MD&A, 2024–2025; EPA final rule April 2024.
No Disclosed Greenhouse Gas Emissions or Net-Zero Target – 10-K does not provide Scope 1, 2, or 3 emissions data, renewable energy percentage, carbon-reduction initiatives, or net-zero commitment date.
Source: TFX 10-K, full-year 2025 filing; absence of climate/ESG addendum.
Supply-Chain Climate & Natural-Disaster Vulnerability – Single-facility manufacturing concentration identified as risk; company acknowledges climate change increases adverse weather and supply-chain disruption risk but identifies no quantified mitigation.
Source: TFX 10-K Item 1A Risk Factors: 'An interruption in our manufacturing or distribution operations,' 'The effects of climate change.'

Disclosed initiatives

Ethylene Oxide Sterilization Regulatory Compliance

Monitoring EPA final rule (April 2024) requiring commercial sterilizers to install pollution control equipment and continuously monitor emissions by April 6, 2026 or April 5, 2027. Teleflex utilizes Sterigenics U.S. LLC facilities (Smyrna, GA; Santa Teresa, NM) for vascular and surgical product sterilization.

Regulatory compliance required; potential supply-chain disruption if contract sterilizers fail to meet deadline; company plans to identify alternative sterilization methods if needed, but no alternatives publicly identified.
Climate Risk & Natural Disaster Preparedness

Company acknowledges climate change could increase frequency and severity of adverse weather, supply-chain interruptions, facility damage, and workforce availability challenges. Risk factors identify hurricanes, tornadoes, earthquakes, wildfires, droughts, and floods as business interruption threats.

Acknowledged risk; no quantified mitigation capex or insurance hedging disclosed.
EU MDR & Climate-Disclosure Compliance Monitoring

10-K notes company subject to EU MDR (effective May 2021), California and EU climate-related disclosure requirements (sustainability, environmental protection, greenhouse gas emissions measurement and reporting).

Compliance obligation identified; no emissions inventory or net-zero target disclosed.

Social story

Teleflex reports moderate social risks with limited transparency on diversity metrics, labor relations, and supply-chain human-rights due diligence. As of December 31, 2025, 6% of workforce covered by union/collective-bargaining agreements (low unionization rate); no recent documented strikes or major labor disputes reported. CEO-to-worker pay ratio not disclosed. Diversity (gender/racial) percentages for workforce and leadership not disclosed in 10-K. Company identifies supply-chain ethics and FCPA compliance as ongoing compliance obligations given 41% international revenue (as of 2025), government-sponsored healthcare customer base abroad, and operations in multiple high-corruption jurisdictions. Recent CEO transition (January 2026) creates short-term retention risk for senior management. Company does not disclose supplier diversity programs, forced-labor or conflict-minerals policies, or living-wage commitments.

Criticisms on file

No Disclosed CEO-to-Worker Pay Ratio – 10-K does not disclose CEO total compensation relative to median worker compensation.
Source: TFX 10-K, 2025 filing; absence of pay-ratio disclosure.
No Disclosed Workforce or Leadership Diversity Metrics – 10-K does not provide gender, racial/ethnic, or other diversity percentages for workforce or executive/board leadership.
Source: TFX 10-K, 2025 filing; absence of EEO-1 or voluntary diversity disclosures.
No Disclosed Supply-Chain Human-Rights or Conflict-Minerals Policy – 10-K does not reference modern slavery statement, forced-labor policy, conflict-minerals sourcing policy, or high-risk geography due diligence (e.g., DRC cobalt, ASM sourcing).
Source: TFX 10-K, 2025 filing; absence of human-rights audit or modern slavery statement.
FCPA Compliance Risk in High-Corruption Jurisdictions – Company operates in 'many parts of the world that have experienced government corruption'; relies on employee training and compliance programs; acknowledges 'we may not always prevent reckless or criminal acts by our employees, distributors or other agents.'
Source: TFX 10-K Item 1A Risk Factors: 'We are subject to risks associated with our non-U.S. operations.'
CEO Transition Risk – Departure of Chairman, President & CEO (Liam J. Kelly) on January 8, 2026; Interim CEO appointed; permanent CEO search ongoing. Risk to retention of other senior management and continuity of business initiatives.
Source: TFX 10-K Item 1A Risk Factors: 'We could be adversely affected by our ongoing CEO transition.' Also MD&A: 'On January 8, 2026, we announced the departure...'

Disclosed initiatives

Healthcare Fraud & Abuse Compliance Program

Company subject to federal anti-kickback statute, false claims laws, HIPAA, state law equivalents. Implemented compliance programs required by California, Connecticut, Nevada, Massachusetts. Subject to Physician Payments Sunshine Act (ACA) annual reporting of transfers of value to physicians and teaching hospitals. Vermont mandates ban on certain items of value to healthcare providers. Failure to report results in civil penalties up to $150,000/year (up to $1M/year for knowing failures).

Compliance infrastructure in place; ongoing monitoring required; penalties risk identified.
FCPA & International Anti-Bribery Compliance

Company mandates FCPA and similar anti-bribery law compliance across international operations. Training and compliance programs implemented; internal control policies and procedures in place. Company acknowledges 76% of employees are non-U.S. based and 41% of revenues are non-U.S.; notes operations in jurisdictions with experienced government corruption.

Compliance programs in place; company acknowledges risk of reckless or criminal acts by employees, distributors, agents; potential exposure to criminal/civil penalties, debarment, disgorgement.
CEO Transition & Leadership Retention Risk

On January 8, 2026, Stuart A. Randle appointed Interim President & CEO; prior CEO Liam J. Kelly departed. Board engaged executive search firm for permanent CEO. Dr. Stephen K. Klasko appointed independent Chair of Board.

Transition risks identified: market for qualified CEO candidates competitive; risk of retention of senior management team; risk to continuity of business initiatives, strategies through transition period.

Governance story

Teleflex exhibits moderate governance risks with significant debt obligations, active M&A/divestiture activity, and disclosed lobbying/regulatory exposure. Board independence percentage not disclosed in 10-K. No dual-class share structure identified. Company does not disclose annual lobbying expenditures or PAC contributions; however, explicitly references compliance with FDA, FTC, state medical device regulations and healthcare anti-kickback laws, suggesting substantial regulatory engagement. Major regulatory risks include FDA 510(k) clearance/PMA approval processes, medical device compliance audits, product liability exposure, and healthcare reimbursement policy changes. Strategic Divestitures announced December 9, 2025 (sale of Acute Care, Interventional Urology, OEM businesses for $2.0B; expected close H2 2026) represent material corporate restructuring. CEO transition (January 2026) and interim leadership create governance transition risk. Total debt $2.7B as of December 31, 2025; leverage ratio covenants in place (max 4.50x); interest coverage minimum 3.50x. No active antitrust proceedings, consumer-safety recalls, or SEC consent decrees explicitly detailed in 10-K; however, product liability and regulatory violation risks are standard medical device industry exposure.

Criticisms on file

Strategic Divestitures Execution Risk – Announced February 2025; definitive agreements signed December 9, 2025. Sales of Acute Care, Interventional Urology (Intersurgical, $530M) and OEM (Montagu/Kohlberg, $1.5B) remain subject to regulatory approvals, closing conditions, and market acceptance. Material diversion of management attention; employee retention risk; potential negative market reaction if transactions delayed or not completed.
Source: TFX 10-K Item 1A Risk Factors: 'The strategic transformation that we are currently implementing may not have the intended results...'; MD&A: 'Strategic Divestitures.'
CEO Transition & Interim Leadership – Liam J. Kelly (Chairman, President, CEO) departed January 8, 2026. Stuart A. Randle appointed Interim President & CEO; Dr. Stephen K. Klasko appointed independent Chair. Permanent CEO search ongoing. Risk to continuity of strategy, retention of senior management, execution of ongoing initiatives.
Source: TFX 10-K Item 1A Risk Factors: 'We could be adversely affected by our ongoing CEO transition'; MD&A: 'On January 8, 2026, we announced the departure...'
No Disclosed Annual Lobbying Expenditure or PAC Contribution Data – 10-K does not report lobbying spend or political PAC contributions; company does not disclose positions on environmental deregulation, consumer-protection rollbacks, or trade-association climate misalignment.
Source: TFX 10-K, 2025 filing; absence of 10-K Item 8 or lobbying-registry cross-reference.
Board Independence Percentage Not Disclosed – 10-K does not report percentage of independent directors; no corporate governance proxy statement (DEF 14A) provided in source documents.
Source: TFX 10-K, 2025 filing; governance section does not provide board composition data.
Italian Payback Measure Regulatory Exposure – 2015 Italian legislation imposes 'payback' measure on medical device companies. Regions invoiced Teleflex for excess expenditures 2015–2018. Company and others filed appeals challenging constitutionality; Italian Constitutional Court upheld law (July 2024). August 2025 legislative modification reduced payment obligation to ~25%. Company remitted payment Q3 2025; reserve $19.4M as of December 31, 2025 (years 2019–2025).
Source: TFX 10-K MD&A: 'Italian payback measure.'
Product Liability & Regulatory Compliance Risk – Medical device industry exposes company to product-liability lawsuits, recalls, FDA enforcement actions (warning letters, product seizures, facility suspension, criminal prosecution possible). Recalls and safety issues could damage reputation, reduce demand, result in material losses.
Source: TFX 10-K Item 1A Risk Factors: 'We may incur material losses and costs as a result of product liability and warranty claims...'; 'We are subject to extensive government regulation...'

Disclosed initiatives

Debt Covenant Compliance & Liquidity Management

Senior Credit Facility (November 4, 2027 maturity): maximum total net leverage ratio 4.50x; minimum interest coverage ratio 3.50x. $500M 2027 Senior Notes and $500M 2028 Senior Notes outstanding. $75M accounts receivable securitization facility fully drawn. As of December 31, 2025, $425M drawn on $1.0B revolving facility; total debt $2.7B. Covenants restrict indebtedness, liens, asset dispositions, dividends, affiliate transactions.

Compliance in place as of December 31, 2025; leverage and interest-coverage covenants monitored quarterly. Strategic Divestitures expected to generate ~$1.8B net after-tax proceeds; proceeds allocated to share repurchases and debt reduction.
Regulatory Compliance Infrastructure (FDA, Healthcare Fraud & Abuse, HIPAA)

Company subject to FDA 510(k) clearance and PMA approval processes for new products; periodic FDA facility inspections; Quality System Regulation (QSR) compliance required; adverse event and product-malfunction reporting mandated; federal anti-kickback statute, false claims laws, HIPAA compliance; state-level medical device tracking and payment-reporting requirements (Connecticut, Massachusetts, Vermont, California, Nevada).

Compliance systems in place; substantial internal and external legal/regulatory costs incurred; failure to comply results in warning letters, product recalls, fines, civil/criminal penalties, exclusion from Medicare/Medicaid, facility shutdown.
Strategic Divestitures & Organizational Transformation

Announced February 2025; definitive agreements signed December 9, 2025. Selling Acute Care and Interventional Urology businesses to Intersurgical Ltd ($530M); OEM business to Montagu and Kohlberg ($1.5B). Board approved; closing expected H2 2026. Multi-year restructuring plan initiated Q1 2026 to eliminate stranded costs, expected savings $48M–$52M annually. Separation costs and integration expenses incurred; management attention diverted.

Material corporate restructuring ongoing; expected benefits contingent on successful transaction completion and integration; risks include regulatory approval delays, key employee retention challenges, market uncertainty regarding post-divestiture company value.
Cross-Currency Swap & Hedging Arrangements

Entered into two cross-currency swap agreements (August 18, 2025) hedging U.S. dollar to Swiss Franc (CHF) exposure; notional $600M total; expiring 2030 and 2032. Terminated 2023 Cross-currency swap agreements (September 30, 2025); executed new swaps hedging USD to Euro exposure; maturity March 2026; notional $500M. Risk: if USD weakens vs. CHF by 10%, company would owe ~$100M; if USD weakens vs. CHF by 10%, company would owe ~$60M.

Hedges in place for material foreign exchange exposure; quarterly fair-value adjustments required; termination and refinancing risks identified.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Teleflex Incorporated. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Teleflex Incorporated in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)